- Home
- PAXS vs LXRX Comparison
PAXS vs LXRX Comparison
Compare PAXS & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAXS | LXRX |
|---|---|---|
| Founded | N/A | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.0M | 660.9M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PAXS | LXRX |
|---|---|---|
| Price | $14.65 | $1.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.15 |
| AVG Volume (30 Days) | 146.3K | ★ 1.9M |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $13.74 | $0.51 |
| 52 Week High | $16.56 | $1.95 |
Technical Indicators
Market Signals| Indicator | PAXS | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.75 | 40.99 |
| Support Level | $14.30 | $1.47 |
| Resistance Level | $14.84 | $1.65 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 65.58 | 6.25 |
Price Performance
Historical ComparisonAbout PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.